Compare Stocks: CVAC, ABCL, RLAY, and TLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.02 -6.3%	$11.26	$2.74 ▼ $15.02	$3.93B	1.41	5.43 million shs	8.47 million shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
RLAY Relay Therapeutics	$17.41 -3.0%	$19.08	$5.85 ▼ $21.27	$3.93B	1.72	3.48 million shs	4.33 million shs
TLX Telix Pharmaceuticals	$11.01 -1.0%	$11.47	$6.28 ▼ $13.11	$3.78B	-0.17	515,095 shs	390,348 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-6.31%	-13.59%	+5.07%	+76.76%	+94.81%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-14.02%
RLAY Relay Therapeutics	-3.01%	-5.84%	-8.90%	-12.95%	+184.94%
TLX Telix Pharmaceuticals	-0.99%	+2.71%	-8.10%	-1.17%	+7.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.02 -6.3%	$11.26	$2.74 ▼ $15.02	$3.93B	1.41	5.43 million shs	8.47 million shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
RLAY Relay Therapeutics	$17.41 -3.0%	$19.08	$5.85 ▼ $21.27	$3.93B	1.72	3.48 million shs	4.33 million shs
TLX Telix Pharmaceuticals	$11.01 -1.0%	$11.47	$6.28 ▼ $13.11	$3.78B	-0.17	515,095 shs	390,348 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-6.31%	-13.59%	+5.07%	+76.76%	+94.81%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-14.02%
RLAY Relay Therapeutics	-3.01%	-5.84%	-8.90%	-12.95%	+184.94%
TLX Telix Pharmaceuticals	-0.99%	+2.71%	-8.10%	-1.17%	+7.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.67	Moderate Buy	$13.38	11.27% Upside
CVAC CureVac	1.00	Sell	N/A	N/A
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	48.86% Upside
TLX Telix Pharmaceuticals	2.80	Moderate Buy	$20.50	86.19% Upside

Current Analyst Ratings Breakdown

Latest CVAC, ABCL, RLAY, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	RLAY Relay Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/29/2026	ABCL AbCellera Biologics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$17.00
9/25/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/24/2026	ABCL AbCellera Biologics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$13.00
9/23/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/21/2026	TLX Telix Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy
9/15/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/14/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/2/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/20/2026	TLX Telix Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	49.05	N/A	N/A	$3.23 per share	3.72
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
RLAY Relay Therapeutics	$15.35M	248.55	N/A	N/A	$3.27 per share	5.32
TLX Telix Pharmaceuticals	$803.79M	4.66	$0.04 per share	263.74	$1.23 per share	8.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/9/2026 (Confirmed)
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	40.78	N/A	N/A	N/A	N/A	N/A

Latest CVAC, ABCL, RLAY, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	RLAY Relay Therapeutics	-$0.40	N/A	N/A	N/A	$1.62 million	N/A
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
CVAC CureVac	0.03	3.70	3.69
RLAY Relay Therapeutics	N/A	18.27	18.27
TLX Telix Pharmaceuticals	1.16	2.01	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CVAC CureVac	17.26%
RLAY Relay Therapeutics	96.98%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
CVAC CureVac	2.15%
RLAY Relay Therapeutics	5.04%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	562	306.61 million	219.53 million	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.89 million	N/A	N/A

CVAC, ABCL, RLAY, and TLX Headlines

Recent News About These Companies

Telix to Host Capital Markets Day in Melbourne on November 4, 2026

4 hours ago | finance.yahoo.com

Telix Pharmaceuticals: Merger Bodes Well For Long-Term Plan

October 8 at 3:56 PM | seekingalpha.com

UBS thinks Telix Pharmaceuticals shares will go how high

October 8 at 10:55 AM | msn.com

Telix Issues 15,000 New Shares From Conversion of Unquoted Securities

October 8 at 5:54 AM | theglobeandmail.com

Australian Shares Flat; Telix Pharmaceuticals Launches US Commercial Availability of Brain Cancer Imaging Drug

October 7 at 7:32 AM | au.finance.yahoo.com

Telix Adds 436,366 New Shares to ASX Listing

October 6 at 11:21 PM | theglobeandmail.com

Telix Pharmaceuticals Reports Lapse of Conditional Equity Securities

October 6 at 11:21 PM | theglobeandmail.com

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

October 6 at 8:19 AM | taiwannews.com.twT

First U.S. Patient Receives Telix's Newly Approved Brain Cancer Imaging Drug

October 6 at 8:19 AM | rttnews.com

First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

October 6 at 6:30 AM | globenewswire.com

Sidley Represents Telix Pharmaceuticals in Its US$1.65 Billion Merger With ITM

October 5, 2026 | sidley.comS

IBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®

October 1, 2026 | biospace.comB

IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®

October 1, 2026 | globenewswire.com

Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade

September 30, 2026 | zacks.com

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging

September 30, 2026 | manilatimes.netM

Telix Pharmaceuticals wins FDA fast track for BiPASS prostate cancer imaging

September 30, 2026 | msn.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - Here's Why

September 28, 2026 | marketbeat.com

Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Has Average Price Target of $20.50 According to Brokerages

September 28, 2026 | americanbankingnews.com

Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Now Rated "Buy" by Wall Street Brokerages

September 28, 2026 | marketbeat.com

Analysts Offer Insights on NA Companies: Ford Motor (F) and Telix Pharmaceuticals Limited Unsponsored ADR (TLX)

September 26, 2026 | theglobeandmail.com

Telix Pharmaceuticals (NASDAQ:TLX) Stock Rating Reaffirmed as Buy by HC Wainwright

September 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, ABCL, RLAY, and TLX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$12.02 -0.81 (-6.31%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$12.15 +0.13 (+1.08%)

As of 10/8/2026 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 10/7/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Relay Therapeutics NASDAQ:RLAY

$17.41 -0.54 (-3.01%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$17.40 0.00 (-0.03%)

As of 10/8/2026 07:30 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$11.01 -0.11 (-0.99%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$10.95 -0.06 (-0.54%)

As of 10/8/2026 07:36 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVAC, ABCL, RLAY, and TLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVAC, ABCL, RLAY, and TLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVAC, ABCL, RLAY, and TLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, ABCL, RLAY, and TLX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

CureVac NASDAQ:CVAC

Relay Therapeutics NASDAQ:RLAY

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVAC, ABCL, RLAY, and TLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVAC, ABCL, RLAY, and TLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVAC, ABCL, RLAY, and TLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, ABCL, RLAY, and TLX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

CureVac NASDAQ:CVAC

Relay Therapeutics NASDAQ:RLAY

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools